high-throughput protein microarray huprot tm v4.0 (CDI Laboratories)
90
Structured Review
CDI Laboratories
high-throughput protein microarray huprot tm v4.0
High Throughput Protein Microarray Huprot Tm V4.0, supplied by CDI Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/high+throughput+microarray/huprot+human+proteome+microarray/pmc12032526-175-1-10
Average 90 stars, based on 1 article reviews
High Throughput Protein Microarray Huprot Tm V4.0, supplied by CDI Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/high+throughput+microarray/huprot+human+proteome+microarray/pmc12032526-175-1-10
Average 90 stars, based on 1 article reviews
high-throughput protein microarray huprot tm v4.0 - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "A Novel IgG–IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules"
Article Title: A Novel IgG–IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules
Journal: Genomics, Proteomics & Bioinformatics
doi: 10.1093/gpbjnl/qzae085
Figure Legend Snippet: Flowchart of the study Early-LUAD, early-stage lung adenocarcinoma; BLD, benign lung disease; NHC, normal healthy control; HuProt TM , Human Proteome Microarray; ELISA, enzyme-linked immunosorbent assay.
Techniques Used: Control, Microarray, Enzyme-linked Immunosorbent Assay
Figure Legend Snippet: Profiling of significant IgM autoantibodies between Early-LUAD and BLD/NHC/Control in the HuProt TM screening The heatmap displays a distinct distribution of significant IgM autoantibodies between Early-LUAD and BLD/NHC/Control, with generally higher levels of IgM observed in Early-LUAD. All values are normalized. The plots on the top display the data on age, sex, smoking, and alcohol consumption for each group, while the bar chart on the right side shows the sensitivity of each autoantibody. Control indicates the BLD+NHC group.
Techniques Used: Control
Figure Legend Snippet: Verification of autoantibodies by focused microarray A . Repeated detection of pooled samples displayed high reproducibility, with an averaged correlation coefficient of 0.95. Pooled samples comprised randomly selected samples from the Early-LUAD, BLD, and NHC groups (10 samples in each group). ***, P < 0.001 ( t -test for Pearson correlation coefficients). B . The top 10/top 15 IgG and IgM autoantibodies with the most significant elevation in Early-LUAD compared to BLD/NHC/Control are displayed. These most significant autoantibodies are ranked based on their FC on the vertical axis and sensitivity on the horizontal axis. C . A descending trend in the signal distribution of IgM autoantibodies across three representative samples from the Early-LUAD, BLD, and NHC groups, respectively. The images on the left visually depict the functionality of the focused microarray, while the 3D bar plots on the right show the distribution of normalized fluorescence intensities. D . IgG and IgM types of autoantibodies showed significantly higher levels in Early-LUAD compared to BLD. *, P < 0.05; **, P < 0.01 (Welch’s t -test). FC, fold change; NS, not significant.
Techniques Used: Microarray, Control, Fluorescence
Related Articles
Microarray:Article Title: Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis Article Snippet: Frozen supernatants from polyclonally stimulated B cells were delivered to Cambridge Protein Arrays Ltd. (Cambridge, United Kingdom). .. Samples were analyzed using HuProt v4.0 Article Title: Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis Article Snippet: Background and Objectives Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease of the CNS.. Highlighted by the success of B-cell–depleting therapies such as the monoclonal anti-CD20 antibodies rituximab, ocrelizumab, and ofatumumab, B cells have been shown to play a central role in the immunopathology of the disease.. Yet, the target antigens of the pathogenic B-cell response in MS remain unclear. Recombinant:Article Title: Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis Article Snippet: Frozen supernatants from polyclonally stimulated B cells were delivered to Cambridge Protein Arrays Ltd. (Cambridge, United Kingdom). .. Samples were analyzed using HuProt v4.0 Article Title: Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis Article Snippet: Background and Objectives Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease of the CNS.. Highlighted by the success of B-cell–depleting therapies such as the monoclonal anti-CD20 antibodies rituximab, ocrelizumab, and ofatumumab, B cells have been shown to play a central role in the immunopathology of the disease.. Yet, the target antigens of the pathogenic B-cell response in MS remain unclear. other:Article Title: Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss Article Snippet: Article Title: Multiomics dissection of human RAG deficiency reveals distinctive patterns of immune dysregulation but a common inflammatory signature. Article Snippet: Marita Bosticardo†, Kerry Dobbs†, Ottavia M. Delmonte†, Andrew J. Martins‡, Francesca Pala, Tomoki Kawai§, Heather Kenney, Gloria Magro, Lindsey B. Rosen, Yasuhiro Yamazaki, HsinHui Yu, Enrica Calzoni, Yu Nee Lee, Can Liu‡, Jennifer Stoddard, Julie Niemela, Danielle Fink, Riccardo Castagnoli¶, Meredith Ramba, Aristine Cheng#, Deanna Riley, Vasileios Oikonomou, Elana Shaw, Brahim Belaid, Sevgi Keles, Waleed AlHerz, Caterina Cancrini, Cristina Cifaldi, Safa Baris, Svetlana Sharapova, Catharina Schuetz, Andrew R. Gennery, Alexandra F. Freeman, Raz Somech, Sharon Choo, Silvia C. Giliani, Tayfun Güngör, Daniel Drozdov, Isabelle Meyts, Despina Moshous, Benedicte Neven, Roshini S. Abraham, Aisha ElMarsafy, Maria Kanariou, Alejandra King, Francesco Licciardi, Mario E. CruzMuñoz, Paolo Palma, Cecilia Poli, Mehdi Adeli, Mattia Algeri**, Fayhan J. Alroqi, Paul Bastard, Jenna R. E. Bergerson, Claire Booth, Ana Brett, Siobhan O. Burns, Manish J. Butte, Nurcicek Padem, M. Teresa de la Morena, Ghassan Dbaibo, Suk See de Ravin, Dimana Dimitrova, Reda Djidjik, Mayra B. Dorna, Cullen M. Dutmer, Reem Elfeky, Fabio Facchetti, Ramsay L. Fuleihan, Raif S. Geha, Luis I. GonzalezGranado, Liis Haljasmägi, Hanadys Ale, Anthony Hayward, Anna M. Hifanova, Winnie Ip, Blanka Kaplan, Neena Kapoor, Elif KarakocAydiner, Jaanika Kärner, Michael D. Keller, Blachy J. Dávila Saldaña††, Ayça Kiykim, Taco W. Kuijpers, Elena E. Kuznetsova, Elena A. Latysheva, Jennifer W. Leiding, Franco Locatelli, Guisela AlvaLozada, Christine McCusker, Fatih Celmeli, Megan Morsheimer, Ahmet Ozen, Nima Parvaneh, Srdjan Pasic, Alessandro Plebani, Kahn Preece, Susan Prockop, Inga S. Sakovich, Elena E. Starkova, Troy Torgerson, James Verbsky, Jolan E. Walter, Brant Ward‡‡, Elizabeth L. Wisner, Deborah Draper, Katherine MyintHpu, Pooi M. Truong, Michail S. Lionakis, Morgan B. Similuk, Centralized Sequencing Program Group§§, Magdalena A. Walkiewicz, Amy Klion, Steven M. Holland, Cihan Oguz, Dusan Bogunovic, Kai Kisand, Helen C. Su, John S. Tsang‡, Douglas Kuhns, Anna Villa, Sergio D. Rosenzweig, Stefania Pittaluga, Luigi D. Notarangelo* Article Title: Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss. Article Snippet: Identification of dexamethasone binding proteins using |